Table 1.

Overview of PCVs

Vaccine Name	Marketed Name	Approval Year	Age Indication	Amount of Serotype per Dose	Carrier Protein	References
PCV7	Prevnar	2000	≥2 mo	2.0 µg for each except 6B (4.0 µg)	CRM197	[4, 5]
PCV10	Synflorix	2011	≥6 wk–5 y	1.0 µg for each except 4, 18C, and 19F (3 µg each)	Protein D, except for 18C (tetanus toxoid) and 19F (diphtheria toxoid)	[6–8]
PCV13	Prevnar 13	2010	≥6 wk	2.2 µg for each except 6B (4.4 µg)	CRM197	[5, 9]
PCV15 (V114)	Vaxneuvance	2021	≥6 wk	2.0 µg for each except 6B (4.0 µg)	CRM197	[10–12]
PCV20	Apexxnar	2021	≥18 y	2.2 µg for each except 6B (4.4 µg)	CRM197	[13, 14]
	Prevnar 20	2023	≥6 wk

Aluminum phosphate was the adjuvant for each vaccine.

Abbreviations: CRM, cross-reacting material; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; V114, 15-valent pneumococcal conjugate vaccine.